JP2021533779A5 - - Google Patents
Info
- Publication number
- JP2021533779A5 JP2021533779A5 JP2021507761A JP2021507761A JP2021533779A5 JP 2021533779 A5 JP2021533779 A5 JP 2021533779A5 JP 2021507761 A JP2021507761 A JP 2021507761A JP 2021507761 A JP2021507761 A JP 2021507761A JP 2021533779 A5 JP2021533779 A5 JP 2021533779A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- linker
- antigen
- optionally
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765095P | 2018-08-16 | 2018-08-16 | |
| US62/765,095 | 2018-08-16 | ||
| PCT/US2019/046705 WO2020037150A2 (en) | 2018-08-16 | 2019-08-15 | Engineered bispecific proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533779A JP2021533779A (ja) | 2021-12-09 |
| JP2021533779A5 true JP2021533779A5 (enExample) | 2022-08-22 |
| JP7397063B2 JP7397063B2 (ja) | 2023-12-12 |
Family
ID=69525976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507761A Active JP7397063B2 (ja) | 2018-08-16 | 2019-08-15 | 操作された二重特異性タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220017634A1 (enExample) |
| EP (1) | EP3850007A4 (enExample) |
| JP (1) | JP7397063B2 (enExample) |
| KR (1) | KR20210064199A (enExample) |
| CN (1) | CN112839955A (enExample) |
| AU (1) | AU2019320803A1 (enExample) |
| BR (1) | BR112021002730A2 (enExample) |
| CA (1) | CA3109763A1 (enExample) |
| EA (1) | EA202190542A1 (enExample) |
| IL (1) | IL280882A (enExample) |
| MA (1) | MA53616A (enExample) |
| MX (1) | MX2021001711A (enExample) |
| SG (1) | SG11202101273VA (enExample) |
| WO (1) | WO2020037150A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CR20230178A (es) * | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| US20240392035A1 (en) * | 2021-08-25 | 2024-11-28 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| KR20240116743A (ko) * | 2021-11-09 | 2024-07-30 | 한양대학교 산학협력단 | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 |
| WO2023114499A1 (en) * | 2021-12-17 | 2023-06-22 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
| US12011489B2 (en) * | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| IL318627A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Anti-TFR charge fusions and methods of using them |
| MA71631A (fr) | 2022-07-29 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Particules virales reciblées vers le récepteur 1 de transferrine |
| CN118221803A (zh) * | 2022-12-19 | 2024-06-21 | 深圳科兴药业有限公司 | 异源二聚体Fc融合蛋白及其用途 |
| KR20260021596A (ko) | 2023-04-05 | 2026-02-13 | 아이오니스 파마수티컬즈, 인코포레이티드 | Pln 발현을 감소시키는 화합물 및 방법 |
| AR133384A1 (es) | 2023-07-28 | 2025-09-24 | Regeneron Pharma | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP4624490A3 (en) * | 2012-02-09 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| US10562973B2 (en) * | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| CA2990785C (en) | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| JP7021955B2 (ja) | 2015-06-24 | 2022-03-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法 |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| JP6932700B2 (ja) * | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| CA3053381A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
| RS63818B1 (sr) * | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| CA3053379A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| BR112020005271A2 (pt) * | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| WO2019094576A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Bace-tau bispecific antibodies |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| BR112020013921A2 (pt) * | 2018-01-10 | 2020-12-01 | Denali Therapeutics Inc. | polipeptídeos de ligação ao receptor de transferrina e usos destes |
| WO2019246071A1 (en) * | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
-
2019
- 2019-08-15 CA CA3109763A patent/CA3109763A1/en active Pending
- 2019-08-15 EP EP19849330.6A patent/EP3850007A4/en not_active Withdrawn
- 2019-08-15 SG SG11202101273VA patent/SG11202101273VA/en unknown
- 2019-08-15 WO PCT/US2019/046705 patent/WO2020037150A2/en not_active Ceased
- 2019-08-15 BR BR112021002730-0A patent/BR112021002730A2/pt not_active IP Right Cessation
- 2019-08-15 EA EA202190542A patent/EA202190542A1/ru unknown
- 2019-08-15 KR KR1020217007602A patent/KR20210064199A/ko not_active Withdrawn
- 2019-08-15 MX MX2021001711A patent/MX2021001711A/es unknown
- 2019-08-15 AU AU2019320803A patent/AU2019320803A1/en not_active Abandoned
- 2019-08-15 CN CN201980066244.0A patent/CN112839955A/zh active Pending
- 2019-08-15 MA MA053616A patent/MA53616A/fr unknown
- 2019-08-15 JP JP2021507761A patent/JP7397063B2/ja active Active
-
2021
- 2021-02-11 US US17/174,231 patent/US20220017634A1/en not_active Abandoned
- 2021-02-15 IL IL280882A patent/IL280882A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514371A5 (enExample) | ||
| AU2015357053B2 (en) | Domain-exchanged antibody | |
| KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| JP2021534220A5 (enExample) | ||
| JP2024150674A5 (enExample) | ||
| JP2023085476A5 (enExample) | ||
| JP2022512234A5 (enExample) | ||
| IL269395B2 (en) | Immunoconjugation of anti-PD-1 antibody with IL-2 or IL-15 mutation | |
| JP2019533441A5 (enExample) | ||
| JP7397063B2 (ja) | 操作された二重特異性タンパク質 | |
| JP2018537966A5 (enExample) | ||
| JP2021521781A5 (enExample) | ||
| JP2018504092A5 (enExample) | ||
| JP2023554500A5 (enExample) | ||
| JP2023545707A5 (enExample) | ||
| JP2024504372A5 (enExample) | ||
| JP2026035742A5 (enExample) | ||
| JPWO2022102768A5 (enExample) | ||
| JP2024500354A5 (enExample) | ||
| JP2024546129A5 (enExample) | ||
| US20250277055A1 (en) | Bi- or multi-specific antibody | |
| JPWO2019216436A1 (ja) | 抗体の抗原結合領域を含み、生理活性ペプチドを融合する人工タンパク質 | |
| JP2024534118A5 (enExample) | ||
| JP2021510162A5 (enExample) | ||
| JP2024534824A5 (enExample) |